Publicaciones (22) Publicaciones de Ana López  Martín

2024

  1. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

2023

  1. Effects of Physical Activity Interventions on Self-Perceived Health Status among Lung Cancer Patients: Systematic Review and Meta-Analysis

    Cancers, Vol. 15, Núm. 23

  2. Immunogenicity of COVID-19 vaccines in lung cancer patients

    Lung Cancer, Vol. 184

  3. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib

    Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e166-e174

2022

  1. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study

    Translational Lung Cancer Research, Vol. 11, Núm. 1, pp. 53-63

2021

  1. Article a multicenter analysis of the outcome of cancer patients with neutropenia and covid-19 optionally treated with granulocyte-colony stimulating factor (G-csf): A comparative analysis

    Cancers, Vol. 13, Núm. 16

  2. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

    Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56

  3. Lung cancer patients with COVID-19 in Spain: GRAVID study

    Lung Cancer, Vol. 157, pp. 109-115

2017

  1. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

    Journal of Thoracic Oncology, Vol. 12, Núm. 4, pp. 752-762

2016

  1. Multidisciplinary approach of unresectable head and neck cancer

    Head and Neck Cancer: Multimodality Management, Second Edition (Springer International Publishing), pp. 617-624

  2. Targeted therapy in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma (LA-R/M HNSCC)

    Cancers, Vol. 8, Núm. 3

2015

  1. Los profesionales de la accesibilidad

    Madrid Accessibility Week: Compartiendo Accesibilidad : Edición 2014 (Universidad Internacional de Andalucía), pp. 63-66

2013

  1. Phase i study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

    Cancer Chemotherapy and Pharmacology, Vol. 72, Núm. 1, pp. 75-83

2012

  1. Toxicidad pulmonar grave relacionada con la administración de gemcitabina

    Farmacia Hospitalaria

2007

  1. Prognostic value of KIT expression in small cell lung cancer

    Lung Cancer, Vol. 56, Núm. 3, pp. 405-413

2005

  1. Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 24, Núm. 4, pp. 291-293

2004

  1. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia

    Cancer, Vol. 100, Núm. 11, pp. 2462-2469

  2. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors

    British Journal of Cancer, Vol. 91, Núm. 12, pp. 2005-2011

2003

  1. Hypervascular pelvic mass: An infrequent cause of digestive hemorrhage [4]

    Revista Clinica Espanola

  2. Tumores del tracto genitourinario

    Oncología en atención primaria (Madrid: Nova sidonia oncología y hematología), pp. 341-354